Business Standard
Thursday, Feb 16, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Commodities
 

Few takers for govt offer on H1N1 vaccine trials
Joe C Mathew / New Delhi Sep 17, 2009, 00:31 IST

The central government’s invitation to global pharmaceutical companies to conduct clinical trials here of their H1N1 (swine flu) vaccine candidates has evoked only a limited response. Only two companies, Novartis and GlaxoSmithKline, have come forward to seek regulatory approval for such trials in India, it is learnt.

Industry sources said this was due to the government’s reluctance to place advance orders with the vaccine makers, to purchase their vaccine as and when it is ready.

Multinational firms Baxter and Sanofi Pasteur are also in various stages of clinical trials to develop the H1N1 vaccine. Several countries have placed advance orders with these drug majors. Incidentally, Sanofi Pasteur, the vaccine division of Sanofi Aventis, said today its H1N1 vaccine had received US regulatory approval.

Health ministry officials said the absence of applications to conduct clinical trials could be considered as lack of interest. “Only two of them have applied. Others might do so in the coming weeks. We are also looking forward to Indian companies to come up with their vaccines,” a senior official said.

He added multinational firms with clinical trial approvals could be ready with their vaccines by December. “Indian companies should be ready by April. We don’t see the need to give advance orders when we have a medicine that is capable of curing the illness. Further, there is no guarantee that the vaccine trials will be successful,” he added.

India has so far registered over 200 deaths due to the H1N1 flu. According to official figures, of the 30,118 samples tested for Influenza A H1N1 in government laboratories and 6,588 in private labs across the country till September 15, as many as 21 per cent were found to be positive.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Wall Street opens flat as data offsets Moody's warning
- Govt to talk to all parties for consensus on Lok Pal
- Kingfisher needs more funds to remain going concern: auditors
- We don't want player retention policy in future IPL: Roy
- ONGC may invoke force majeure clause for 2 KG blocks
  Read Business news in 
- Now property search gets more exciting than ever before!
- High Growth Business Opportunities in Africa - Register to explore
- Medium-sized businesses are the engines of a smarter planet.
- Save over Rs.3000 with IndianOil Citibank Card
- We live for our family. have you secured them?
- India's No. 1 Property Site. Click here to know more..
- Diseases earlier, Saving Costs, Extending Lives. Know More..
- Get 5% cashback on telephone bills with Citi
- Enjoy the journey as much as the destination. click to know more..
- Exim Bank Conclave on India - Africa Project Partnership. Know more..
- Be part of it The World's Largest Aircraft.
- Creating Wealth made simple the SIP way. Know more..
- Only Developer to give a guarantee on time space & rate.
- Office 365 for professionals and small businesses.
- Buy Your Property with Our Triple Guarantee in India.
- Improve Patient Care & Experience. Click here to know more
- Win a Business Class Ticket to Europe..Know more..
-  Introduce a New Automotive Luxury Car.. know more
- Health is Wealth..... Insurance + Savings... Know More...
Sorry, comments to this story are closed
Latest Messages
Posted by: caBouthillier
The vaccine will cause debilitating and chronic symptoms or death to those with blood types A, B & O. These blood types have damaged DNA and weakened immune systems. The blood type AB is the normal healthy blood type with normal DNA and immune system. For explanation see: http://www.unveilingthem.com/PoisoningOfMankindCopperDeficiency.htm C.A. Bouthillier
SmartInvestor+ E-zine
  Pay Rs.747/- for 3 years and
  get a branded watch FREE

  Subscribe Now
Most Popular
Read
E-Mailed
Commented
   
- Leela parts ways with Kempinski
- Kanika Datta: The importance of being SRK
- Nestle: Food for thought
- Tailor-made but not good enough
- Star-studded jury honours corporate excellence
 
 More  
BUSINESS STANDARD INDIA 2012
  Now available at Special price
  Rs.395/- Only
  Buy Now
  Now available on the Kindle Store...
  BS Specials  
    Full coverage of elections in Uttar Pradesh, Punjab, Uttarakhand, Manipur and Goa
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us